Pomerantz brings to DIA more than 30 years of executive experience with specialized expertise in health policy, medical society management, and health administration.
“It’s not often that the timing around an exciting new strategy coincides with the start of new, passionate leadership, but DIA is fortunate to have both,” said DIA Board President Jeff Sherman. “I know Paul agrees that for us to truly meet our mission, we need to build relationships with new scientific, industry, academic, patient, and regulatory stakeholders who can contribute to the value of our global, multidisciplinary, and neutral educational and networking forum. We hope that this new vision and mission will help to reinforce the work we’re doing together to raise the level of health worldwide.”
To see the complete and expanded DIA Vision and Mission Statements, please visit www.diahome.org.
About the Drug Information Association (DIA)
As a nonprofit member-driven association, DIA serves more than 30,000 professionals involved in the biopharmaceutical industry, academia, research organizations and governmental bodies worldwide. DIA fosters innovation of products, technologies, and services to improve health and well being worldwide by providing indispensible forums to exchange vital information and discuss current issues, delivering customized learning experiences, building, maintaining, and facilitating trusted relationships with and among individuals and organizations that drive and share DIA values and mandates, and providing a multidisciplinary neutral environment, respected globally for integrity and relevancy. DIA is led by its volunteer Board of Directors and executive management team, has headquarters in Horsham, PA, USA, and offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China. For mo
'/>"/>
| Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved |